Market Place
Sourcing Support
Turn Therapeutics Appoints Dr. Kent Kester To Board Of Directors
15 Oct 2025 //
GLOBENEWSWIRE
Turn Therapeutics Appoints Arthur Golden To Board Of Directors
14 Oct 2025 //
GLOBENEWSWIRE
Turn Therapeutics To Commence Trading Today On Nasdaq
08 Oct 2025 //
GLOBENEWSWIRE
Turn Therapeutics To Debut On Nasdaq Global Market
29 Sep 2025 //
BUSINESSWIRE
Turn Therapeutics` Investor Session Ahead of Nasdaq Listing
15 Sep 2025 //
BUSINESSWIRE
Turn Therapeutics` Intranasal Vaccine Shows Extended Stability
06 Aug 2025 //
BUSINESSWIRE
Turn Therapeutics Starts Eczema Trial With IL-36/IL-31 Drug
14 Jul 2025 //
BUSINESSWIRE
Turn Therapeutic Validate 100% VSV Recovery from Petrolatum Carrier
02 May 2025 //
BUSINESSWIRE
Turn Therapeutics Achieves Stability for Intranasal Live Vaccine
05 Feb 2025 //
BUSINESSWIRE
Turn Therapeutics` AD Candidate Shows Promising Cytokine Inhibition
05 Aug 2024 //
PR NEWSWIRE
Turn`s Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
20 Jun 2024 //
BUSINESSWIRE
Turn Therapeutics Invites Investment For Wound, Eczema, Toenail Formulas
22 May 2024 //
BUSINESSWIRE
MIMEDX Announces Wound Surgical Product Pipeline Expansion Agreement with Turn
08 Dec 2022 //
GLOBENEWSWIRE
Turn Therapeutics Announces Trial Data for COVID-19 Early Intervention Candidate
25 Aug 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.